-- New approval for VIMPAT® (lacosamide) CV in the U.S. as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older -- All three ...
ATLANTA, June 24, 2024 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that Epilepsia published findings from a comprehensive scoping review examining the efficacy of ...
The FDA also approved Vimpat Injection for use in pediatric patients 4 years of age and older. The Food and Drug Administration (FDA) has approved Vimpat ® (lacosamide; UCB) as adjunctive therapy in ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. DENVER — Primary generalized tonic-clonic seizures ...
WOODCLIFF LAKE, N.J., June 22, 2015 /PRNewswire/ -- Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved FYCOMPA® (perampanel) CIII for adjunctive therapy in the ...
Seizures occur when the normal electrical activity in your brain is disrupted. This can lead to symptoms like unconsciousness, uncontrollable shaking, or lip-smacking. Your symptoms largely depend on ...
A phase 3 study assessing the use pregabalin as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized tonic-clonic (PGTC) seizures did not meet its primary endpoint to ...
Dear Dr. Roach: My husband suffered a grand mal seizure about six months ago. He was in the hospital for seven days. When he came out of the seizure, he was very combative and experienced memory loss.
Dear Dr. Roach: My husband suffered a grand mal seizure about six months ago. He was in the hospital for seven days. When he came out of the seizure, he was very combative and experienced memory loss.
Xenon nears a Q3 2026 NDA with strong Phase 3 epilepsy data and a cash runway to 2029. Click here to read an analysis of XENE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results